

Health Care Systems Research Collaboratory

## Uses of the NIH Collaboratory Distributed Research Network

Jeffrey Brown, PhD for the DRN Team
Harvard Pilgrim Health Care Institute and
Harvard Medical School
March 11, 2016

### The Goal

The NIH Collaboratory DRN facilitates research partnerships with organizations (Data Partners) that possess <u>electronic</u> <u>health data that have been quality checked and formatted</u> to support multi-site biomedical research

## Collaboratory DRN Objective

**Goal:** Facilitate multisite research collaborations between investigators and data stewards by creating secure networking capabilities and analysis tools.

- Advantages of a distributed research network (DRN)
  - √ Ability to work with analysis-ready datasets covering many millions
  - √ Standardized data using a common data model
  - ✓ Data stewards keep and analyze their own data
  - ✓ Provide results, not data, to the requestor
  - ✓ All activities audited and secure

### Uses of the Distributed Network

- Research planning
  - Assess background rates and population impact of conditions / treatments
  - Prioritize research domains
  - Identify sites for participation in interventional or observational studies
- Answer research questions!

Requestors do not have to be experts in use of healthcare data

- Coordinating Center helps requestors understand and use the network
  - Assess fit between requests and DRN capabilities
  - Suggest ways to maximize usefulness of DRN data and resources

## NIH Collaboratory Distributed Research Network Partners

NIH Collaboratory Distributed Research Network
Millions of people. Strong collaborations. Privacy first.

#### **Data Partners**


















The **Meyers** Primary Care Institute

All participate in FDA's Sentinel System







• Each organization can participate in multiple networks



- Each organization can participate in multiple networks
- Each network controls its governance and coordination




- Each organization can participate in multiple networks
- Each network controls its governance and coordination
- Networks share infrastructure, data curation, analytics, lessons, security, software development




- Each organization can participate in multiple networks
- Each network controls its governance and coordination
- Networks share infrastructure, data curation, analytics, lessons, security, software development

### Medical Product Safety National Evidence Generation Concept Surveillance



### Medical Product Safety National Evidence Generation Concept Surveillance



### Available Data

- Rapid-response distributed querying available across data partners with over 90 million lives
- >300 million person-years of observation time
- Detailed information for billions of medical encounters and outpatient pharmacy dispensings
- Analysis-ready datasets (i.e., quality checked and formatted) representing >90% of the FDA Sentinel program

#### **Data Elements**

- Available
  - Ambulatory care diagnoses and procedures
  - Outpatient pharmacy dispensing
  - Laboratory testing and selected test results
  - Inpatient diagnoses, treatments, and procedures itemized in hospital bill

- Not available
  - Out-of-hospital death
  - OTC medication
  - Community-based immunizations

### Pilot Test of the Collaboratory DRN

- Special NIH supplement in 2014 for pilot test
- Three pilot test queries developed by 3 NIH Institutes
- Pilot used publically-available Sentinel querying tools
- DRN Team and NIH staff (led by NHLBI & NCI) used queries as test cases for developing processes, and refining strategies to format queries
  - Assess recruitment feasibility of replicating the Trial to Assess Chelation Therapy (TACT)
  - Characterize statin users >75 years of age
  - Assess rates of abnormal cancer screening test results and rates of follow up testing

## Diabetes and Chelation Therapy

- Rationale: Assess recruitment feasibility of replicating the Trial to Assess Chelation Therapy (TACT)
- Goal: Characterize individuals with prevalent diabetes and prior
   AMI but no prior heart failure or chelation therapy
  - Simple counts: Counts and prevalence of chelation therapy and diabetes
  - **Complex counts**: First diagnosis of diabetes in people over 50 years of age in 2007 through 2014 with evidence of a prior AMI but no evidence of heart failure or chelation therapy
    - Any care setting
    - 365 day "look-back" window

## Statin Users >75 years old and Cardiovascular Disease (CVD)

- Rationale: Characterize statin users over the age of 75 with regard to CVD and diabetes status
- Complex counts: All and long-term (>=180 days) prevalent and incident statin users
  - With no evidence of CVD
  - With and without a evidence of a diabetes diagnosis the day of or in the 90 days before first statin dispensing

# Abnormal Cancer Screening Results and Follow-up

- Rationale: Characterize frequency of abnormal breast, colorectal, and cervical cancer screening test results and follow-up care
- Background rates: Incidence of cancer screenings and abnormal cancer screening results
  - 270 day "look-back" window to define new screen and new result
- Abnormal screening results and follow-up: For each cancer, count patients with a new abnormal finding, and among them, count how many had a follow-up test within 90 days
  - 183 day "look-back" window to define new abnormal result

## Results: Cancer Screening and Abnormal Cancer Screen Result

- Breast cancer
  - Screening (2007-2014)
    - 6,719,382 eligible members (female, ages 40+, meets enrollment/incidence requirements, etc)
    - 3,750,337 new patients with a breast cancer screening
    - 8,809,583 new breast cancer screenings
  - Abnormal Results (2007-2014)
    - 6,898,880 eligible members (female, ages 40+, meets enrollment/incidence requirements, etc)
    - 1,075,964 patients with a new abnormal result
    - 1,418,562 new abnormal results

# Results: Abnormal Cancer Screen Result and Follow-up

- Breast cancer continued...
  - Follow-up after Abnormal Result (2013 only)
    - 220,735 patients with a new abnormal result
    - 216,179 patients with a follow-up procedure/diagnosis
    - 97.9% follow-up within 90 days
    - 3.1 mean time to follow-up (days)

## Results: Cancer Screening and Abnormal Cancer Screen Result

- Colorectal cancer
  - Screening (2007-2014)
    - 8,735,964 eligible members (ages 50+, meets enrollment/incidence requirements, etc)
    - 2,630,125 new patients with a colorectal cancer screening
    - 3,966,484 new colorectal cancer screenings
  - Abnormal Results (2007-2014)
    - 8,856,555 eligible members (ages 50+, meets enrollment/incidence requirements, etc)
    - 69,531 patients with a new abnormal result
    - 72,616 new abnormal results

# Results: Abnormal Cancer Screen Result and Follow-up

- Colorectal cancer continued...
  - Follow-up after Abnormal Result (2013 only)
    - 12,121 patients with a new abnormal result
    - 8,545 patients with a follow-up procedure/diagnosis
    - 70.5% follow-up within 90 days
    - 32.0 mean time to follow-up (days)

## Results: Cancer Screening and Abnormal Cancer Screen Result

- Cervical cancer
  - Screening (2007-2014)
    - 10,808,847 eligible members (female, ages 21+, meets enrollment/incidence requirements, etc)
    - 5,322,691 new patients with a cervical cancer screening
    - 10,703,839 new cervical cancer screenings
  - Abnormal Results (2007-2014)
    - 11,216,026 eligible members (female, ages 21+, meets enrollment/incidence requirements, etc)
    - 768,962 patients with a new abnormal result
    - 927,948 new abnormal results

# Results: Abnormal Cancer Screen Result and Follow-up

- Cervical cancer continued...
  - Follow-up after Abnormal Result (2013 only)
    - 126,620 patients with a new abnormal result
    - 93,430 patients with a follow-up procedure/diagnosis
    - 73.8% follow-up within 90 days
    - 25.0 mean time to follow-up (days)


## Summary of NIH Pilot Test

- Test cases assessed in three data organizations, representing ~1/3 of the total data
- Test cases informative of the necessary iterative process needed to refine queries
- Pilot informative of types of queries that are readily addressed vs. those that require a more iterative process over time to address
- Manual updated based on experience of the team with the test cases
- Revised processes and timelines for future test cases

## Comparing Collaboratory DRN and PCORnet

- Collaboratory DRN is based on administrative claims and outpatient pharmacy dispensing data
  - Complete data for most reimbursed care → if no evidence of an event, it very likely didn't occur
  - Limited access to medical record information
- PCORnet is based on EHR data
  - Detailed information care provided by clinical organization, including vital signs, lab test results
  - Limited information about care provided by other organizations or drug dispensing

#### https://www.nihcollaboratory.org/Pages/distributed-research-network.aspx



## **Next Steps**

- Exploring possibilities for testing additional NIH queries to refine process
- Considering pilot testing of external queries from the research community
- For additional information, please go to:
   <u>https://www.nihcollaboratory.org/Pages/distributed-research-network.aspx#HowSubmit</u>